Breakthrough: GSK boss Emma Walmsley (pictured) has been pushing to boost the firm’s drug pipeline

Breakthrough: GSK boss Emma Walmsley (pictured) has been pushing to boost the firm’s drug pipeline

Breakthrough: GSK boss Emma Walmsley (pictured) has been pushing to boost the firm’s drug pipeline

GSK has scored another win for its drug pipeline. European watchdogs have given a cancer treatment developed by the pharma giant the thumbs up.

Jemperli has been cleared by the European Commission for use alongside chemotherapy to treat endometrial cancer, which affects the uterus.

EU regulators also green lit Jemperli for use by itself, or after chemo. It follows similar approvals for the drug in the US.

GSK head of oncology research Hesham Abdullah said: ‘With this approval, we can expand the number of patients who can potentially benefit from treatment with Jemperli in Europe.’

The drugs giant has invested heavily in Jemperli and is aiming to expand its use to several different types of cancer. 

Last month, the company’s blood cancer drug Blenrep reached a key goal in a late-stage clinical trial following a series of setbacks.

GSK boss Emma Walmsley has been pushing to boost the company’s drug pipeline after splitting off its consumer health business Haleon last year.

The strategy appears to be working, with GSK upgrading its profit guidance for the second time this year after big sales of its vaccine Arexvy, which protects against respiratory syncytial virus (RSV).

#fiveDealsWidget .dealItemTitle#mobile {display:none} #fiveDealsWidget {display:block; float:left; clear:both; max-width:636px; margin:0; padding:0; line-height:120%; font-size:12px} #fiveDealsWidget div, #fiveDealsWidget a {margin:0; padding:0; line-height:120%; text-decoration: none; font-family:Arial, Helvetica ,sans-serif} #fiveDealsWidget .widgetTitleBox {display:block; float:left; width:100%; background-color:#af1e1e; } #fiveDealsWidget .widgetTitle {color:#fff; text-transform: uppercase; font-size:18px; font-weight:bold; margin:6px 10px 4px 10px; } #fiveDealsWidget a.dealItem {float:left; display:block; width:124px; margin-right:4px; margin-top:5px; background-color: #e3e3e3; min-height:200px;} #fiveDealsWidget a.dealItem#last {margin-right:0} #fiveDealsWidget .dealItemTitle {display:block; margin:10px 5px; color:#000; font-weight:bold} #fiveDealsWidget .dealItemImage, #fiveDealsWidget .dealItemImage img {float:left; display:block; margin:0; padding:0} #fiveDealsWidget .dealItemImage {border:1px solid #ccc} #fiveDealsWidget .dealItemImage img {width:100%; height:auto} #fiveDealsWidget .dealItemdesc {float:left; display:block; color:#004db3; font-weight:bold; margin:5px;} #fiveDealsWidget .dealItemRate {float:left; display:block; color:#000; margin:5px} #fiveDealsWidget .dealFooter {display:block; float:left; width:100%; margin-top:5px; background-color:#e3e3e3 } #fiveDealsWidget .footerText {font-size:10px; margin:10px 10px 10px 10px;} @media (max-width: 635px) { #fiveDealsWidget a.dealItem {width:19%; margin-right:1%} #fiveDealsWidget a.dealItem#last {width:20%} } @media (max-width: 560px) { #fiveDealsWidget #desktop {display:none;} #fiveDealsWidget #mobile {display:block!important} #fiveDealsWidget a.dealItem {background-color: #fff; height:auto; min-height:auto} #fiveDealsWidget a.dealItem {border-bottom:1px solid #ececec; margin-bottom:5px; padding-bottom:10px} #fiveDealsWidget a.dealItem#last {border-bottom:0px solid #ececec; margin-bottom:5px; padding-bottom:0px} #fiveDealsWidget a.dealItem, #fiveDealsWidget a.dealItem#last {width:100%} #fiveDealsWidget .dealItemContent, #fiveDealsWidget .dealItemImage {float:left; display:inline-block} #fiveDealsWidget .dealItemImage {width:35%; margin-right:1%} #fiveDealsWidget .dealItemContent {width:63%} #fiveDealsWidget .dealItemTitle {margin: 0px 5px 5px; font-size:16px} #fiveDealsWidget .dealItemContent .dealItemdesc, #fiveDealsWidget .dealItemContent .dealItemRate {clear:both} }

This post first appeared on Dailymail.co.uk

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Sir Vince Cable admits to ME & MY MONEY some of his early financial decisions left a lot to be desired

‘I’ve never been a spendthrift’: But Sir Vince Cable enjoys the finer…

MARKET REPORT: Plus 500 cashes in on day trading boom 

The pandemic craze for day trading shows no sign of waning despite…

Record day for property sales and Rightmove traffic has surged

Home sales hit their highest daily level in a decade this week,…

Why won’t power firms repair our  broken smart meters? 

Raymond Edgell and his wife Sandra decided to get a smart meter…